Komori
Treasury Stock4577Daito Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice Regarding the Status of Share Buybacks and Completion of the Buyback

The company acquired 116,800 treasury shares from 1 April to 22 April 2026 and completed the share repurchase conducted pursuant to the resolution of the Board of Directors made in October 2025. The cumulative number of shares acquired reached the maximum of 1 million shares.

Worth reading
72In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
116800
Shares
Wording
Definitive
How definitive the wording is.

Progress against acquisition limit

Acquisition completedMarket purchases on the Tokyo Stock Exchange

Resolved 10 October 2025 / Acquisition period 15 October 2025 to 22 May 2026 ※2 (based on contract date)

100.0%
Cumulative utilization rate
Limit
Number of Shares1,000,000 shares (maximum)
—
No Track Record Reported
Limit
Amount¥1.5 billion (maximum)

The darker band is the portion acquired this time (1 April 2026 to 22 April 2026 ※1 (on a settlement-date basis)).

Number of Shares
Limit1,000,000 shares (maximum)
Cumulative total1,000,000 shares (as of 22 April 2026)
Current116,800 shares
Amount
Limit¥1.5 billion (maximum)
Cumulative total¥1,344,434,100 (as of 22 April 2026)
Current¥163,912,800
Percentage of total issued shares3.3%
Average acquisition price for this transaction (calculated)¥1,403 per shareCurrent acquisition price ÷ current number of shares acquired
Whether acquisition has been completed

The share repurchase pursuant to the resolution of the Board of Directors made on 10 October 2025 has been completed in full

消化率と残りは、会社が示した累計・今回と上限から算出しています。進捗率=上限に対してどこまで使ったかの割合です。

Progress against acquisition limit
ItemDetails
Total number of shares acquired in this transaction116,800 shares
Total current acquisition price¥163,912,800
Acquisition date/acquisition period1 April 2026 to 22 April 2026 ※1 (on a settlement-date basis)
Method of acquisitionMarket purchases on the Tokyo Stock Exchange
Cumulative number of shares acquired1,000,000 shares (as of 22 April 2026)
Cumulative acquisition cost¥1,344,434,100 (as of 22 April 2026)
Resolution date10 October 2025
Maximum number of shares to be acquired1,000,000 shares (maximum)
Total acquisition price¥1.5 billion (maximum)
Acquisition period under the resolution15 October 2025 to 22 May 2026 ※2 (based on contract date)
Percentage of total issued shares3.3%
Whether acquisition has been completedThe share repurchase pursuant to the resolution of the Board of Directors made on 10 October 2025 has been completed in full
Items this document does not state (1)
Average Acquisition Price

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company conducted the share repurchase pursuant to Article 459, Paragraph 1 of the Companies Act and the provisions of its Articles of Incorporation. No specific reason for completing the repurchase is stated, but the disclosure says that the repurchase was completed because the cumulative number of shares acquired reached the limit set in the resolution.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Status of Share Buybacks and Completion of the Buyback | Daito Pharmaceutical Co.,Ltd. (4577) timely disclosure | Komori